Comparison of IV Lignocain and IV Dexmedetomidine for Attenuation of Laryngoscopic Stress Response to Direct Laryngoscopy

Comparison of Intravenous Lignocain and Intravenous Dexmedetomidine for Attenuation of Hemodynamic Stress Response to Direct Laryngoscopy and Endotracheal Intubation

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07385040

Enrollment

Registered

2026-02-03

Start date

2023-04-13

Completion date

2023-12-31

Last updated

2026-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Mean Arterial Pressure, Tachycardia

Keywords

Direct laryngoscopy, Hemodynamic stress response, Lignocaine, Dexmedetomidine

Brief summary

Hemodymanic stress response to direct laryngoscopy and endotracheal intubation is a known phenomenon that occur in almost every patient undergoing general anesthesia before surgical procedure. This response leads to sudden rise in heart rate and blood pressure which may cause serious complications in compromised patients having cardiovascular diseases. There are certain drugs which are used to blunt this response and to prevent the life threatening complications. Intravenous Lignocain is commonly used drug to blunt the laryngoscopic response in our setup. Intravenous Dexmedetomidine is a newer and rarely used drug to prevent stress response to direct laryngoscopy and endotracheal intubation. This study aims to compare the efficacy of both the drugs to provide better control of complications like Arrythmias, stroke and cardiovascular instability.

Interventions

DRUGIntravenous Dexmedetomidine infusion

Dexmedetomidine infusion with dose of 10mics/kg given 10min before induction

DRUGIntravenous Lignocain

Intravenous ligoncain 1.5mg/kg given 90sec before induction.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Intervention model description

Single blinded, randomised control trial

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

Patients undergoing general anesthesia for any elective surgery Having ASA 1 or 2 Having mallapatti 1 or 2 Having BMI in between 18-30 kg/m2

Exclusion criteria

Lack of consent Anticipated difficult airway Pregnancy Sensitivity to either drug

Design outcomes

Primary

Measure	Time frame	Description
Hemodynamic stress response	1 minute and 3 minute after endotracheal intubation	Rise in Heart rate and mean arterial pressure

Countries

Pakistan

Contacts

PRINCIPAL_INVESTIGATORMaryam Maryam

Shaheed Mohtarma Benazir Bhutto Institue of Trauma

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026